product_96

Liver In Vivo Transfection Kit

$495.00$2,985.00

Kit Size VolumePriceAdd to Cart
0.5 ml - 10 injections (Catalog #5060)$495.00
1.5 ml - 30 injections (Catalog #5061)$995.00
8.0 ml - 160 injections (Catalog #5062)$2,985.00
SKU: LIVIV

Product Description

NOTE: To place order using Credit Card, P-Card, or Purchase Order – please choose kit size above and click “Add to cart” button. You can place order online without creating an account.

Liver In Vivo Transfection Reagent
siRNA and DNA liver in vivo delivery reagent for animal research (mouse, rat)

Modes of administration:

  • Systemic intravenous (i.v.) injection
  • Direct intratumoral (i.t.) injection
  • Intraperitoneal (i.p.) injection

Liver-targeted In Vivo Transfection Reagent

  • Biodegradable lipid liposome-based reagent
  • Liposome conjugated complexes are stable in serum (16h)
  • Efficient delivery to the liver tissue (via systemic administration) and liver tumors (via intratumoral administration)
  • Efficient siRNA, shRNA, microRNA, and plasmid DNA delivery
  • Minimal toxicity
  • Functionally validated in mice
  • Applicable for plasmid DNA/siRNA co-injection
  • Download Liver-targeted in vivo transfection protocol: [PDF] [Word]
  • Download PowerPoint presentation for Liver-targeted in vivo transfection kit: [PPT]
  • Developed and manufactured by Altogen Biosystems

DATA

In Vivo Liver Transfection Reagent Liver Hepatocarcinoma Tumors

Figure 1. Systemic administration (i.v.) of Liver In Vivo Transfection Reagent conjugated with 80 ug of chemically modified siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues (Liver, Brain, Muscle, Kidney, Tumor, Heart, Spleen, Lung) were collected and RNA isolated 24 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

Figure 2. Intratumoral administration (i.t.) of Liver In Vivo Transfection Reagent conjugated with 80 ug of chemically modified siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Animal model is NOD/SCID xenograft mouse bearing flank tumor of human origin (liver cancer cell line). Tissues (Liver, Brain, Muscle, Kidney, Tumor, Heart, Spleen, Lung) were collected and RNA isolated 24 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).

Liver-Targeted-Transfection-Altogen-Catalog-5062-4 Liver-Targeted-Transfection-Altogen-Catalog-5062-1 Liver-Targeted-Transfection-Altogen-Catalog-5062-2 Liver-Targeted-Transfection-Altogen-Catalog-5062-3

Figure 3. Systemic administration (i.v.) of Liver In Vivo Transfection Reagent conjugated with 80 ug of chemically modified siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues (Liver, Brain, Muscle, Kidney, Tumor, Heart, Spleen, Lung) were collected and total protein fraction isolated 72 hours after first injection. Samples were analyzed by Western Blot Analysis for Lamin A/C gene expression levels.

Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):

  • Nature. 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]
  • Am J Pathology. 2010 177(4):1870-80. Role of ocular complement factor H in a murine model … Lyzogubov et al [PDF]
  • Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]
  • Cancer Research. 2011 71(15):5144-53. Inhibition of miR-193a expression by… Iliopoulos et al [PDF]
  • RNA. 2010 16(11):2108-19. RNase L releases a small RNA from HCV RNA that refolds … Malathi et al [PDF]
  • Diabetologia. 2012 55(7):2069-79. The p47phox- and NADPH oxidase organiser 1 … Youn et al [PDF]
  • British Journal of Cancer. 2012 107(3):516-26. TIGAR induces p53-mediated cell-cycle … Madan et al [PDF]
  • Hypertension. 2014 63(2):353-61. Tissue transglutaminase contributes to … Liu et al [PDF]
  • Circulation Research. 2010 15;107(8). Kruppel-like factor-4 transcriptionally regulates … Cowan et al [PDF]
  • Hypertension. 2012 59(1):158-66. Role of uncoupled endothelial nitric oxide synthase … Gao et al [PDF]
  • Jounal of Biological Chemistry. 2012 287(4):2907. Chaperoning of mutant p53 protein … Gogna et al [PDF]
  • PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF]
  • J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced … Kim et al [PDF]
  • J Transl Med. 2010 15;8:133. Prevention of hyperglycemia-induced myocardial apoptosis … Zhang et al [PDF]
  • Mol Cell Biol. 2013 33(7). SCO2 induces p53-mediated apoptosis by Thr845 phosphorylation … Madan et al [PDF]
  • Hypertension. 2015 65(2):430-9. Neurokinin 3 receptor and phosphocholine transferase… Parchim et al [PDF]
  • Gastroenterology. 2011 141(2) Differential type I interferon-mediated autophagic trafficking … Desai et al [PDF]
  • PLoS Pathog. 2014 10(10) Exosomes from hepatitis C infected patients transmit HCV … Bukong et al [PDF]

Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

Volume Options:

  • 0.5 ml – 10 injections (Catalog #5060)
  • 1.5 ml – 30 injections (Catalog #5061)
  • 8.0 ml – 160 injections (Catalog #5062)

Additional Information

Kit Size (Volume)

0.5 ml – 10 injections (Catalog #5060), 1.5 ml – 30 injections (Catalog #5061), 8.0 ml – 160 injections (Catalog #5062)